Description
Presenting basic and clinical research on all forms of interferon (IFN) involvement in the management of multiple sclerosis (MS), this text details topics from IFN-receptor molecular interactions to synergy and interference with other agents such as cytotoxic drugs and chemotherapy. It features research findings on IFN beta-1a (Avonex) and IFN beta-1b (Betaseron), and covers the newly discovered IFN-tau – the potentially effective and less toxic type 1 IFN.
